Showing Results for
- Academic Journals (54)
Search Results
- 54
Academic Journals
- 54
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedReNeuron will be treating the first stroke patients with stem cells later this year in the UK after overcoming a string of regulatory holdups abroad. In February, the Surrey-based company received the go-ahead to start...
- 2From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedLast month, President Obama kept his election promise and signed into law the most comprehensive piece of legislation concerning healthcare provision in the United States since the introduction of Medicare by Lyndon...
- 3From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedAlthough metastases are more deadly than primary tumors, the development of antimetastatic therapies has been hampered by a limited understanding of the underlying biology and a resulting lack of suitable drug targets...
- 4From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedOXiGENE (S. San Francisco, CA, USA) has announced the resignation of Arthur B. Laffer from its board of directors to pursue other longstanding interests. Laffer has served on the OXiGENE board since 1998 and had served...
- 5From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedThe US Patent and Trademark Office has issued a patent for detection of RNA-mediated gene silencing to Sir David Baulcombe, University of Cambridge, and Andrew Hamilton, University of Glasgow, over a decade after their...
- 6From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedThe resistance of many Pseudomonas aeruginosa strains to frontline antibiotics complicates the management of hospital-acquired infections. Srinivas et al. describe a potential breakthrough in addressing this problem...
- 7From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedCompugen (Tel Aviv) has announced the appointments of Anat Cohen-Dayag as president and CEO and Martin Gerstel as chairman. Cohen-Dayag and Gerstel previously served as co-CEOs of the company. CohenDayag joined Compugen...
- 8From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedThe number of drug approvals for orphan indications has doubled in recent years, according to a report from the Tufts Center for the Study of Drug Development. The independent, nonprofit research group at Tufts...
- 9From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedWith 5.6 million new hectares (35%) of transgenic crops, Brazil supplanted Argentina to become the 2nd largest cultivator. China's transgenic plantings shrank, although biosafety certificates were issued for Bacillus...
- 10From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedProlonged culture of human embryonic stem cells (hESCs) can lead to adaptation and the acquisition of chromosomal abnormalities, underscoring the need for rigorous genetic analysis of these cells. Here we report the...
- 11From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedIn February, Isis announced its cholesterol-lowering antisense therapy, mipomersen, had met its endpoints in a phase 3 trial of 124 patients with heterozygous familial hypercholesterolemia (FH) and coronary artery...
- 12From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedDevelopmental biologists have traditionally considered lineage commitment and differentiation to be unidirectional and irreversible processes enforced by stable epigenetic patterns. But recent advances in stem cell...
- 13From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedThe V3D system provides three-dimensional (3D) visualization of gigabyte-sized microscopy image stacks in real time on current laptops and desktops. V3D streamlines the online analysis, measurement and proofreading of...
- 14From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedThe US Environmental Protection Agency (EPA) has issued long-awaited regulations governing renewable fuel standards, but the reception in political circles has been frosty. Part of the backlash, from both Republican and...
- 15From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedRecent patent applications in high-throughput drug screening Patent number Description US 20100056390 A three-dimensional cell culture system comprising a cell of interest and a natural or synthetic hydrogel...
- 16From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedCraig W. Carlson has joined Hana Biosciences (S. San Francisco, CA, USA) as CFO. He has held senior leadership and financial management positions for the past 25 years, most recently as CFO and COO for 20 Cent Ventures....
- 17From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedThe US Food and Drug Administration (FDA) and the makers of erythropoietin stimulating agents (ESAs) have agreed on a formal strategy to reduce the risks associated with these drugs. Starting in March, drug makers will...
- 18From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedMicroRNAs (miRNAs) are increasingly implicated in the regulation of metastasis. Despite their potential as targets for anti-metastatic therapy, miRNAs have only been silenced in normal tissues of rodents and nonhuman...
- 19From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedAdeona Pharmaceuticals (Ann Arbor, MI, USA) has named Jeff Lucero Riley as a member of its board of directors. Riley has more than 19 years of experience in the biotech and pharma industries. He is currently managing...
- 20From: Nature Biotechnology. (Vol. 28, Issue 4) Peer-ReviewedThe power of familial genomic studies is illustrated in two recent papers in which separate groups sequenced total genomes of multiple members of families with genetic disorders. Using Complete Genomics' (Mountain View,...